title: Chemotherapy-related acute rhabdomyolysis.
authors.forename: C
authors.initials: C
authors.lastname: Papakonstantinou
authors.forename: K
authors.initials: K
authors.lastname: Papanastasiou
authors.forename: M
authors.initials: M
authors.lastname: Kotsopoulou
authors.forename: M
authors.initials: M
authors.lastname: Mouratidou
authors.forename: D
authors.initials: D
authors.lastname: Sotiropoulos
authors.forename: M C
authors.initials: MC
authors.lastname: Kyrtsoni
authors.forename: A
authors.initials: A
authors.lastname: Pouli
authors.forename: M
authors.initials: M
authors.lastname: Stamatelou
authors.forename: A
authors.initials: A
authors.lastname: Maniatis
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003561:Cytarabine / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D008775:Methylprednisolone / Q000009:adverse effects; D008875:Middle Aged; D011239:Prednisolone / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000139:chemically induced*; D013866:Thioguanine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
chemical_list: D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D011239:Prednisolone; D013866:Thioguanine; D008775:Methylprednisolone